[Anticoagulant therapy in venous thromboembolism].
Venous thromboembolism (VTE) is a common cause of morbidity and mortality with an estimated annual incidence of 1 : 1,000. Patients show individual risk profiles with regard to recurrent VTE and treatment-associated bleeding, which are characterized by the presence of endogenous factors (such as hereditary thrombophilic disorders), but much more by exogenous factors (underlying disease). This results in risk-adapted therapeutic recommendations, which will be discussed in the following review.
Beyer
Jan
J
Arbeitsbereich Angiologie, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Fetscherstrasse 74, 01307 Dresden.
Schellong
Sebastian
S
D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D006470:Hemorrhage / Q000139:chemically induced* / Q000517:prevention & control*; D006801:Humans; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians'; D054556:Venous Thromboembolism / Q000150:complications / Q000517:prevention & control*
D005343:Fibrinolytic Agents